Real-World Survival Outcomes in EGFR-Mutant Advanced NSCLC Treated With EGFR TKIs: Insights From a Single-Center Clinical Data Warehouse Analysis in South Korea.

However, these differences did not reach statistical significance (exon 19 deletion: HR 0.73; 95% CI, 0.47–1.14; p = 0.168; exon 21 L858R: HR: 0.55; 95% CI, 0.30–1.03; p = 0.063) (Figure 3 ). 4.

also in 111,027 other papers

Meanwhile, in the EGFR mutation subtype analysis, first‐line treatment with 3G EGFR TKIs showed a trend toward superior survival benefit compared with 1G/2G EGFR TKIs in patients with an exon 19 deletion or an exon 21 L858R mutation.

also in 53,322 other papers